Search on Site

Explore our comprehensive database of pharmaceutical news releases, press releases, events, and industry insights with ease. Effortlessly find relevant information tailored to your interests and stay updated on the latest developments in the pharmaceutical sector. Start searching now to uncover valuable insights and resources for your pharmaceutical endeavors.

SmartLab Exchange Europe 2027

The invitation-only forum for senior laboratory, digital transformation, data and R&D leaders exploring AI, laboratory automation and connected laboratory ecosystems. Operationalising AI & Digital Transformation to Accelerate Product...

Estrella Immunopharma Highlights ARTEMIS® T-Cell Therapy Data at ASH 2026, Demonstrating Promising Leukemia Treatment Results

Estrella Immunopharma, Inc. a clinical-stage biopharmaceutical company developing next-generation ARTEMIS T-cell therapies for cancer and autoimmune diseases, highlighted preclinical findings from an abstract accepted for poster presentation at...

BE BOLD: BIMZELX® (bimekizumab-bkzx) demonstrates superior joint response rates versus SKYRIZI® (risankizumab-rzaa) at Week 16, with sustained clinical improvements through Week 24

UCB, a global biopharmaceutical company, announced Week 24 data for BIMZELX® (bimekizumab-bkzx) from BE BOLD, building on the study's previously reported Week 16 results, which demonstrated statistically significant superiority in ACR50 joint...

Johnson & Johnson announces that ICOTYDE® (icotrokinra), a once-daily targeted oral peptide, delivers significant improvements in psoriatic arthritis disease activity among biologic-naïve patients

Johnson & Johnson announced positive results from a Phase 3 study investigating ICOTYDE® (icotrokinra) in biologic-naïve adults with active psoriatic arthritis (PsA).a,b ICOTYDE is the first and only targeted oral peptide that precisely blocks the...

Superpower Launches Peptide Services, Connecting Comprehensive Blood Testing With Prescription Peptide Care

Superpower, the human health company on a mission to enhance and extend human life, announces the launch of Superpower Peptides. Members can now sign up for pre-orders for prescribed peptide treatments, following clinical consults. The...

Alchemy 21/12 Introduces Oleotide™, a Breakthrough Modular Biotechnology Platform for Advanced Skincare

Alchemy 21/12 introduced Oleotide™ — a modular biotechnology platform built around the coordination of biological signals and the conditions that support skin renewal. The company describes its first-of-its-kind architecture through five...

CELSET Launches Korean Botulinum Toxin Type A Brand SOLTOX in International Markets

CELSET INC., a Korean biotechnology company specializing in medical aesthetics, has launched SOLTOX, its botulinum toxin type A brand, introducing a Korean botulinum toxin brand to the international medical aesthetics industry. SOLTOX is presented...

Stevanato Group and Aptar Pharma Collaborate to Accelerate Pre-Filled Syringe System Selection

Stevanato Group S.p.A. a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, today announced a collaboration with Aptar Pharma to provide...

Pythia Labs Launched AI-Designed Antibodies for Hard-to-Drug Targets

Pythia Labs, a biotechnology company building frontier AI models for therapeutic discovery, announced its launch alongside a preprint in bioRxiv introducing Pythia-1, the all-atom generative model at the core of its antibody design platform....

Pythia Labs Launched AI-Designed Antibodies for Hard-to-Drug Targets

Pythia Labs, a biotechnology company building frontier AI models for therapeutic discovery, announced its launch alongside a preprint in bioRxiv introducing Pythia-1, the all-atom generative model at the core of its antibody design platform....

Zai Lab Reports High Response Rates, Encouraging Durability, and a Favorable Safety Profile for Zocilurtatug Pelitecan (Zoci; Formerly ZL-1310) in First-Line Extensive-Stage Small Cell Lung Cancer

Zai Lab Limited an innovation-driven, global biopharma company, shared the first data from a global Phase 1b clinical trial evaluating zocilurtatug pelitecan (zoci, formerly ZL-1310) in combination with atezolizumab with and without carboplatin as...

Niagen Bioscience Establishes Skincare as a Permanent Tru Niagen® Category with the Launch of Dermatologist-Tested Niagen NanoCloud™ as a Core Product

Niagen Bioscience, Inc. the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced the debut of Tru Niagen® Skincare, a permanent new category in the core Tru Niagen line, led by...

2nd International Conference on Drug Discovery 2026

The 2nd International Conference on Drug Discovery 2026, organized by Scisynopsis Conferences, aims to bring together researchers, scientists, industry leaders, and academicians from around the world to explore groundbreaking innovations in drug...

The meeting will focus on Nordic Pharma, Inc.’s patient data and study results on LACRIFILL® Canalicular Gel, a novel ocular surface therapy

Nordic Pharma, Inc., a subsidiary of SEVER Life Sciences B.V., will be held at the annual meeting of the American Academy of Ophthalmology from 9 to 12. October in New Orleans, Louisiana, introduce the LACRIFILL ® Canalicular Gel – a novel therapy...

Arkayli Biopharma Inc. Receives FDA Study May Proceed Response to IND and NIH SBIR Grant to Advance Clinical Development of ARK001 for a Rare Pediatric Disease

Arkayli BioPharma Inc. a biopharmaceutical company dedicated to developing innovative therapies for rare dermatologic conditions, announced that the U.S. Food and Drug Administration (FDA) has responded to its Investigational New Drug (IND)...

MedaSystems Announces Major Platform Update to Help Life Sciences Organizations Govern and Scale Expanded Access Programs

MedaSystems, a SaaS platform for managing Expanded Access, Post-Trial Access and Investigator-Initiated Study programs, announced the release of MedaSystems Version 3.3, one of the company’s most significant platform updates to date. The release...

Dr. Oregonin Completes U.S. FDA Registration for OLTIS DENTAL-X, Unveiling Oral Care Innovation Rooted in Trans-Pacific Alder Research

Dr. Oregonin Inc. announced that it has completed U.S. Food and Drug Administration (FDA) registration for OLTIS DENTAL-X, paving the way for its official commercial entry into the North American oral-care market. The product's authorization...

Aptar Pharma Launched Premia™ Precision, Establishing a New Quality Standard for Demanding Injectable Therapies

Aptar Pharma, a global leader in drug delivery, dosing, protection technologies and services, announced the launch of Premia™ Precision, a new quality standard for elastomer components, designed to support sensitive and high-value injectable...

Niagen Bioscience Puts 25 Years of NAD+ Science Behind “Don’t Get Old. Age Better.®” — a New Campaign for Its Niagen® Brand Featuring Legendary Surfer Kelly Slater

Niagen Bioscience, Inc. the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced the launch of “Don't Get Old. Age Better.®,” a new brand campaign for its Niagen® (patented...

Upsher-Smith Launched Fluvoxamine Maleate Extended-Release Capsules

Upsher-Smith Laboratories, LLC a subsidiary of Bora Pharmaceuticals Co., Ltd. (6472.TW and BORAY.OTCQX), today announced the recent launch of Fluvoxamine Maleate Extended-Release Capsules in 100 mg and 150 mg strengths. According to IQVIA, the...